NewsJanuary 28, 2026
PHC Group CEO Kyoko Deguchi Named a Top 50 Healthcare Technology CEO of 2025 by The Healthcare Technology Report — Award recognizes leaders advancing platforms that speed critical decisions,
overcome administrative barriers, and support research and care delivery —
TOKYO, JAPAN, January 28, 2026 – PHC Holdings Corporation (headquarters: Chiyoda-ku, Tokyo, Japan, President & CEO: Kyoko Deguchi, hereafter PHC Group), a global healthcare company dedicated to providing precision technology that powers the future of healthcare, announces that CEO Kyoko Deguchi has been named to the “Top 50 Healthcare Technology CEOs of 2025”*1 list published by The Healthcare Technology Report*2, a leading healthcare technology industry publication.
Each year, The Healthcare Technology Report recognizes companies and executives that create innovative solutions to the most pressing issues in healthcare. The Top 50 Healthcare Technology CEOs of 2025 list reflects individuals who have strengthened healthcare through tools that move information, reduce delays, and help teams act faster and with greater confidence across care delivery and research.
PHC Group is comprised of a network of established companies that are leaders in their respective fields, with 361.6B JPY in total revenue in FY24. PHC Group companies have been providing innovative precision and digital health solutions for more than 50 years to advance research, diagnosis, treatment, and prevention of disease. Collectively, PHC Group seeks to provide precision technology that powers the future of healthcare.
Deguchi became CEO of PHC Group in April 2024 after serving as an independent director, bringing over two decades of experience as a business leader, including in the healthcare industry. In 2025 she led PHC Group through the first year of implementing its Value Creation Plan 2027, which outlines PHC Group’s global strategy to focus future growth on diagnostics and life sciences, including key product launches for PHC Group’s Epredia (precision cancer diagnostics support) and PHCbi (biomedical laboratory equipment) brands. During this time, PHC Group also announced a commitment to achieve net zero greenhouse gas emissions by 2050 and achieved ESG milestones including receiving validation for greenhouse gas reduction targets from the Science Based Targets Initiative and earning a Bronze Medal from EcoVadis for sustainability activities.
As CEO, Deguchi is a vocal proponent of the concept of “One PHC,” a company mindset that seeks to create synergies across divisions and disciplines to create greater value for researchers, healthcare providers, and the patients they serve.
*1 https://thehealthcaretechnologyreport.com/
*2 https://thehealthcaretechnologyreport.com/the-top-healthcare-technology-ceos-of-2025/
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TSE 6523) is a global collection of healthcare companies with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex Corporation and Mediford Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries and regions.
www.phchd.com